DUBLIN--(BUSINESS WIRE)--The "2018 Pancreatitis Drug Development- Pipeline Analysis Report" report has been added to ResearchAndMarkets.com's offering.
Around 25 companies and universities are focusing on developing treatment options for Pancreatitis.
This report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Pancreatitis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Pancreatitis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
- AzurRx BioPharma
- Bessor Pharma LLC
- Bharat Serums And Vaccines Ltd
- Centeer BioTherapeutics
- DiaMedica Therapeutics
- Generon (Shanghai) Corp
- GNT Pharma
Key Topics Covered
1 Table of Contents
2 Pancreatitis Pipeline Analysis
3 Pancreatitis - Company Wise Pipeline Analysis
4 Pancreatitis R&D Pipeline Snapshots
5 Recent Developments in Pancreatitis Pipeline
For more information about this report visit https://www.researchandmarkets.com/research/477qdr/2018_pancreatitis?w=4